Johnson & Johnson (JNJ) Prepaid Assets (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Prepaid Assets came in at $4.8 billion in Q1 2026, up 17.77% year-on-year from $4.1 billion in Q1 2025, and up 16.01% quarter-over-quarter from $4.2 billion in Q4 2025.
Johnson & Johnson (JNJ) Prepaid Assets (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Prepaid Assets across 18 years of filings, most recently posting $4.8 billion for Q1 2026.
- Prepaid Assets for Q1 2026 came in at $4.8 billion, up 17.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 17.77% YoY), and the FY2025 annual result was $4.2 billion, up 1.66% from the prior year.
- Prepaid Assets came in at $4.8 billion for Q1 2026 at Johnson & Johnson, up from $4.2 billion in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $4.8 billion in Q1 2026 to a low of $2.4 billion in Q3 2023.
- The 5-year median for Prepaid Assets is $4.1 billion (2025), against an average of $3.9 billion.
- Across the five-year window, Prepaid Assets plunged 35.27% in 2023 and jumped 82.69% in 2024, its largest moves.
- Johnson & Johnson's Prepaid Assets stood at $3.6 billion in 2022, then advanced by 25.67% to $4.5 billion in 2023, then dropped by 9.5% to $4.1 billion in 2024, then increased by 1.66% to $4.2 billion in 2025, then gained by 16.01% to $4.8 billion in 2026.
- The last three Prepaid Assets figures came in at $4.8 billion (Q1 2026), $4.2 billion (Q4 2025), and $4.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 4.82 Bn |
| Dec 28, 2025 | 4.15 Bn |
| Sep 28, 2025 | 4.29 Bn |
| Jun 29, 2025 | 4.36 Bn |
| Mar 30, 2025 | 4.09 Bn |
| Dec 29, 2024 | 4.09 Bn |
| Sep 29, 2024 | 4.18 Bn |
| Jun 30, 2024 | 4.38 Bn |
| Mar 31, 2024 | 4.46 Bn |
| Dec 31, 2023 | 4.51 Bn |
| Oct 1, 2023 | 4.20 Bn |
| Jul 2, 2023 | 2.40 Bn |
| Apr 2, 2023 | 2.92 Bn |
| Jan 1, 2023 | 2.88 Bn |
| Oct 2, 2022 | 3.59 Bn |
| Jul 3, 2022 | 3.70 Bn |
| Apr 3, 2022 | 3.45 Bn |
| Jan 2, 2022 | 3.70 Bn |
| Oct 3, 2021 | 3.59 Bn |
| Jul 4, 2021 | 3.49 Bn |